TY - CHAP
T1 - Autoimmune interstitial lung disease
AU - Herrán, María
AU - Galindo, Javier Leonardo
AU - Chaves, Juan José
AU - Carrillo-Bayona, Jorge Alberto
AU - Polo, Fernando
AU - Rojas, Manuel
AU - Anaya, Juan Manuel
N1 - Publisher Copyright:
© 2024 Elsevier Inc. All rights are reserved including those for text and data mining AI training and similar technologies.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Interstitial lung diseases (ILDs) describe a large group of parenchymal disorders with a heterogeneous course and presentation. They are common in most autoimmune diseases (ADs), increasing morbidity and mortality among them. Pathogenesis is a result of both hereditary (epigenetics and genetics) and environmental factors, resulting in humoral and cellular immune responses, including fibroblast activation. ILDs are classified depending on their radiologic and pathologic patterns. In ADs, the most common patterns are nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing pneumonia (OP), lymphoid interstitial pneumonia (LIP), and diffuse alveolar damage (DAD). A holistic approach through nonpharmacological and pharmacological therapies is necessary to achieve better outcomes. Further research is still needed to develop tailored therapies. This chapter aims to describe the main elements to understand, diagnose, and evaluate ILDs associated with ADs in clinical practice.
AB - Interstitial lung diseases (ILDs) describe a large group of parenchymal disorders with a heterogeneous course and presentation. They are common in most autoimmune diseases (ADs), increasing morbidity and mortality among them. Pathogenesis is a result of both hereditary (epigenetics and genetics) and environmental factors, resulting in humoral and cellular immune responses, including fibroblast activation. ILDs are classified depending on their radiologic and pathologic patterns. In ADs, the most common patterns are nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing pneumonia (OP), lymphoid interstitial pneumonia (LIP), and diffuse alveolar damage (DAD). A holistic approach through nonpharmacological and pharmacological therapies is necessary to achieve better outcomes. Further research is still needed to develop tailored therapies. This chapter aims to describe the main elements to understand, diagnose, and evaluate ILDs associated with ADs in clinical practice.
UR - https://www.scopus.com/pages/publications/105011564997
UR - https://www.scopus.com/pages/publications/105011564997#tab=citedBy
U2 - 10.1016/B978-0-443-23947-2.00007-2
DO - 10.1016/B978-0-443-23947-2.00007-2
M3 - Chapter
AN - SCOPUS:105011564997
SN - 9780443239465
SP - 969
EP - 1000
BT - The Rose and Mackay Textbook of Autoimmune Diseases, Seventh Edition
PB - Elsevier
ER -
